Moberg Pharma´s Interim report January - June 2023
MOB-015 IS RECOMMENDED FOR APPROVAL IN 13 EUROPEAN COUNTRIESSIX-MONTH PERIOD (JAN-JUN 2023) · EBITDA SEK -10.7 million (-9.1) · Operating profit (EBIT) SEK -12.0 million (-10.4) · Profit after tax SEK -8.9 million (-8.3) · Total profit SEK -8.9 million (-8.3) · Diluted earnings per share SEK -0.90 (-1.34) · Cash and cash equivalents amounted to SEK 52.0 million (160.0) SECOND QUARTER (APR-JUN 2023) · EBITDA SEK -4.7 million (-4.3) · Operating profit (EBIT) SEK -5.3 million (-4.9) · Profit after tax SEK -3.9 million (-3.9) · Total profit SEK -3.9 million (